Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Josiah T Austin. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at Josiah T Austin har rapporteret besiddelser eller handler i følgende virksomheder:
Sikkerhed | Titel | Senest indberettede beholdninger |
---|---|---|
US:GDPMQ / Goodrich Petroleum Corp. | Director | 0 |
US:PRGB / Protea Biosciences Group Inc | Director, 10% Owner | 66.667 |
US:NVGN / Novogen Ltd. | 10% Owner | 385.749 |
US:CHTP / Chelsea Therapeutics International, Ltd. | 10% Owner | 6.432.673 |
US:MEIP / MEI Pharma, Inc. | 10% Owner | 1.000.000 |
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Josiah T Austin. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb KZIA / Kazia Therapeutics Limited - Depositary Receipt (Common Stock) – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i KZIA / Kazia Therapeutics Limited - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg KZIA / Kazia Therapeutics Limited - Depositary Receipt (Common Stock) – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i KZIA / Kazia Therapeutics Limited - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb LITS / Lite Strategy, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i KZIA / Kazia Therapeutics Limited - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg LITS / Lite Strategy, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i KZIA / Kazia Therapeutics Limited - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af Josiah T Austin som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2016-10-11 |
|
4 | GDPMQ |
GOODRICH PETROLEUM CORP
10.00% Series E Cumulative Convertible Preferred Stock |
S - Sale | -13.912 | 0 | -100,00 | 0,00 | -14 | ||
2016-10-11 |
|
4 | GDPMQ |
GOODRICH PETROLEUM CORP
Common Stock |
S - Sale | -316.319 | 323 | -99,90 | 0,01 | -4.492 | 5 | |
2016-03-16 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Director Stock Option (right to buy) |
A - Award | 66.667 | 66.667 | |||||
2016-03-16 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Common Stock |
A - Award | 100.000 | 4.841.411 | 2,11 | ||||
2016-03-16 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
10% Convertible Promissory Note |
P - Purchase | 200.000,00 | ||||||
2016-03-16 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Common Stock |
J - Other | 90.910 | 4.741.411 | 1,95 | ||||
2016-03-16 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Common Stock |
J - Other | 913.945 | 10.493.254 | 9,54 | ||||
2016-03-16 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Common Stock |
J - Other | 1.712.333 | 14.229.810 | 13,68 | ||||
2016-03-16 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Common Stock |
J - Other | 142.504 | 12.517.477 | 1,15 | ||||
2016-03-16 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Common Stock |
J - Other | 5.700.248 | 12.374.973 | 85,40 | ||||
2015-12-18 |
|
4 | GDP |
GOODRICH PETROLEUM CORP
10.00% Series E Cumulative Convertible Preferred Stock |
P - Purchase | 13.912 | 13.912 | |||||
2015-12-18 |
|
4 | GDP |
GOODRICH PETROLEUM CORP
9.75% Series D Cumulative Preferred Stock |
S - Sale | -13.912 | 0 | -100,00 | ||||
2015-06-18 |
|
4 | GDP |
GOODRICH PETROLEUM CORP
Depositary Shares |
P - Purchase | 6.912 | 83.912 | 8,98 | 6,23 | 43.036 | 522.461 | |
2015-06-18 |
|
4 | GDP |
GOODRICH PETROLEUM CORP
Depositary Shares |
P - Purchase | 7.000 | 77.000 | 10,00 | 6,99 | 48.930 | 538.230 | |
2015-06-09 |
|
4/A | GDP |
GOODRICH PETROLEUM CORP
Common Stock |
A - Award | 63.636 | 70.642 | 908,31 | 2,75 | 174.999 | 194.266 | |
2015-06-02 |
|
4 | GDP |
GOODRICH PETROLEUM CORP
Common Stock |
A - Award | 63.636 | 153.242 | 71,02 | 2,75 | 174.999 | 421.416 | |
2014-11-04 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
C - Conversion | |||||||
2014-11-04 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
C - Conversion | |||||||
2014-11-04 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
C - Conversion | 2.850.124 | 11.455.333 | 33,12 | ||||
2014-11-04 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
C - Conversion | 2.850.124 | 11.455.333 | 33,12 | ||||
2014-11-04 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Series A Convertible Preferred Stock |
C - Conversion | 712.531 | 712.531 | |||||
2014-11-04 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Series A Convertible Preferred Stock |
C - Conversion | 712.531 | 712.531 | |||||
2014-09-12 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 174.545 | 11.892.680 | 1,49 | 139.636,00 | 24.372.765.620 | 1.660.646.264.480 | |
2014-09-12 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 174.545 | 11.892.680 | 1,49 | 139.636,00 | 24.372.765.620 | 1.660.646.264.480 | |
2014-09-12 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 290.909 | 11.718.135 | 2,55 | 160.000,00 | 46.545.440.000 | 1.874.901.600.000 | |
2014-09-12 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 290.909 | 11.718.135 | 2,55 | 160.000,00 | 46.545.440.000 | 1.874.901.600.000 | |
2014-08-19 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 185.455 | 11.427.226 | 1,65 | 148.364,00 | 27.514.845.620 | 1.695.388.958.264 | |
2014-08-19 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 185.455 | 11.427.226 | 1,65 | 148.364,00 | 27.514.845.620 | 1.695.388.958.264 | |
2014-08-19 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 309.091 | 11.241.771 | 2,83 | 170.000,00 | 52.545.470.000 | 1.911.101.070.000 | |
2014-08-19 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 309.091 | 11.241.771 | 2,83 | 170.000,00 | 52.545.470.000 | 1.911.101.070.000 | |
2014-07-15 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 130.909 | 10.932.680 | 1,21 | 104.727,00 | 13.709.706.843 | 1.144.946.778.360 | |
2014-07-15 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 130.909 | 10.932.680 | 1,21 | 104.727,00 | 13.709.706.843 | 1.144.946.778.360 | |
2014-07-15 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 218.182 | 10.801.771 | 2,06 | 120.000,00 | 26.181.840.000 | 1.296.212.520.000 | |
2014-07-15 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 218.182 | 10.801.771 | 2,06 | 120.000,00 | 26.181.840.000 | 1.296.212.520.000 | |
2014-07-15 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Stock Option |
A - Award | 12.375 | 10.583.589 | 0,12 | 6.806,00 | 84.224.250 | 72.031.906.734 | |
2014-07-02 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 218.182 | 10.571.214 | 2,11 | 174.546,00 | 38.082.795.372 | 1.845.163.118.844 | |
2014-07-02 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 218.182 | 10.571.214 | 2,11 | 174.546,00 | 38.082.795.372 | 1.845.163.118.844 | |
2014-07-02 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 363.636 | 10.353.032 | 3,64 | 200.000,00 | 72.727.200.000 | 2.070.606.400.000 | |
2014-07-02 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 363.636 | 10.353.032 | 3,64 | 200.000,00 | 72.727.200.000 | 2.070.606.400.000 | |
2014-06-24 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 27.273 | 9.989.396 | 0,27 | 21.818,00 | 595.042.314 | 217.948.641.928 | |
2014-06-24 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 27.273 | 9.989.396 | 0,27 | 21.818,00 | 595.042.314 | 217.948.641.928 | |
2014-06-24 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 45.455 | 9.962.123 | 0,46 | 25.000,00 | 1.136.375.000 | 249.053.075.000 | |
2014-06-24 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 45.455 | 9.962.123 | 0,46 | 25.000,00 | 1.136.375.000 | 249.053.075.000 | |
2014-06-09 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 163.637 | 9.916.668 | 1,68 | 130.909,00 | 21.421.556.033 | 1.298.181.091.212 | |
2014-06-09 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 163.637 | 9.916.668 | 1,68 | 130.909,00 | 21.421.556.033 | 1.298.181.091.212 | |
2014-06-09 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 272.727 | 9.753.031 | 2,88 | 150.000,00 | 40.909.050.000 | 1.462.954.650.000 | |
2014-06-09 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 272.727 | 9.753.031 | 2,88 | 150.000,00 | 40.909.050.000 | 1.462.954.650.000 | |
2014-05-30 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 190.909 | 9.480.304 | 2,06 | 152.727,00 | 29.156.958.843 | 1.447.898.389.008 | |
2014-05-30 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 190.909 | 9.480.304 | 2,06 | 152.727,00 | 29.156.958.843 | 1.447.898.389.008 | |
2014-05-30 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 318.182 | 9.289.395 | 3,55 | 175.000,00 | 55.681.850.000 | 1.625.644.125.000 | |
2014-05-30 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 318.182 | 9.289.395 | 3,55 | 175.000,00 | 55.681.850.000 | 1.625.644.125.000 | |
2014-05-21 |
|
4 | GDP |
GOODRICH PETROLEUM CORP
Common Stock |
A - Award | 7.006 | 89.606 | 8,48 | 24,98 | 175.010 | 2.238.358 | |
2014-05-16 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 54.546 | 8.971.213 | 0,61 | 46.636,00 | 2.543.807.256 | 418.381.489.468 | |
2014-05-16 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 54.546 | 8.971.213 | 0,61 | 46.636,00 | 2.543.807.256 | 418.381.489.468 | |
2014-05-16 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 90.909 | 8.916.667 | 1,03 | 50.000,00 | 4.545.450.000 | 445.833.350.000 | |
2014-05-16 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 90.909 | 8.916.667 | 1,03 | 50.000,00 | 4.545.450.000 | 445.833.350.000 | |
2014-05-12 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 109.091 | 8.825.758 | 1,25 | 87.273,00 | 9.520.698.843 | 770.250.377.934 | |
2014-05-12 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 109.091 | 8.825.758 | 1,25 | 87.273,00 | 9.520.698.843 | 770.250.377.934 | |
2014-05-12 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 181.818 | 8.716.667 | 2,13 | 100.000,00 | 18.181.800.000 | 871.666.700.000 | |
2014-05-12 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 181.818 | 8.716.667 | 2,13 | 100.000,00 | 18.181.800.000 | 871.666.700.000 | |
2014-05-12 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 54.546 | 8.534.849 | 0,64 | 46.636,00 | 2.543.807.256 | 398.031.217.964 | |
2014-05-12 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 54.546 | 8.534.849 | 0,64 | 46.636,00 | 2.543.807.256 | 398.031.217.964 | |
2014-05-12 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 90.909 | 8.480.303 | 1,08 | 50.000,00 | 4.545.450.000 | 424.015.150.000 | |
2014-05-12 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 90.909 | 8.480.303 | 1,08 | 50.000,00 | 4.545.450.000 | 424.015.150.000 | |
2014-05-12 |
|
4 | PRGB |
Protea Biosciences Group, Inc.
Stock Option |
A - Award | 12.375 | 8.389.394 | 0,15 | 6.806,00 | 84.224.250 | 57.098.215.564 | |
2014-04-04 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 190.909 | 8.377.019 | 2,33 | 152.728,00 | 29.157.149.752 | 1.279.405.357.832 | |
2014-04-04 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 190.909 | 8.377.019 | 2,33 | 152.728,00 | 29.157.149.752 | 1.279.405.357.832 | |
2014-04-04 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 318.182 | 8.186.110 | 4,04 | 175.000,00 | 55.681.850.000 | 1.432.569.250.000 | |
2014-04-04 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 318.182 | 8.186.110 | 4,04 | 175.000,00 | 55.681.850.000 | 1.432.569.250.000 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Convertible Note |
C - Conversion | -254.584 | 7.809.970 | -3,16 | 127.292,00 | -32.406.506.528 | 994.146.701.240 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Convertible Note |
C - Conversion | -254.584 | 7.809.970 | -3,16 | 127.292,00 | -32.406.506.528 | 994.146.701.240 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 127.292 | 8.059.970 | 1,60 | 95.469,00 | 12.152.439.948 | 769.477.275.930 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 127.292 | 8.059.970 | 1,60 | 95.469,00 | 12.152.439.948 | 769.477.275.930 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 254.584 | 7.932.678 | 3,32 | 127.292,00 | 32.406.506.528 | 1.009.766.447.976 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 254.584 | 7.932.678 | 3,32 | 127.292,00 | 32.406.506.528 | 1.009.766.447.976 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
P - Purchase | 254.584 | 6.674.725 | 3,97 | 0,50 | 127.292 | 3.337.362 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
P - Purchase | 254.584 | 6.674.725 | 3,97 | 0,50 | 127.292 | 3.337.362 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 303.417 | 7.678.094 | 4,11 | 227.563,00 | 69.046.482.771 | 1.747.250.104.922 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 303.417 | 7.678.094 | 4,11 | 227.563,00 | 69.046.482.771 | 1.747.250.104.922 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 606.833 | 7.374.677 | 8,97 | 303.417,00 | 184.123.448.361 | 2.237.602.371.309 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 606.833 | 7.374.677 | 8,97 | 303.417,00 | 184.123.448.361 | 2.237.602.371.309 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 319.375 | 6.767.844 | 4,95 | 239.531,00 | 76.500.213.125 | 1.621.108.441.164 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 319.375 | 6.767.844 | 4,95 | 239.531,00 | 76.500.213.125 | 1.621.108.441.164 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 638.750 | 6.448.469 | 10,99 | 319.375,00 | 204.000.781.250 | 2.059.479.786.875 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 638.750 | 6.448.469 | 10,99 | 319.375,00 | 204.000.781.250 | 2.059.479.786.875 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 513.056 | 5.809.719 | 9,69 | 384.792,00 | 197.419.844.352 | 2.235.533.393.448 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 513.056 | 5.809.719 | 9,69 | 384.792,00 | 197.419.844.352 | 2.235.533.393.448 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 1.026.111 | 5.296.663 | 24,03 | 513.056,00 | 526.452.405.216 | 2.717.484.732.128 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 1.026.111 | 5.296.663 | 24,03 | 513.056,00 | 526.452.405.216 | 2.717.484.732.128 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 50.000 | 4.270.552 | 1,18 | 37.500,00 | 1.875.000.000 | 160.145.700.000 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 50.000 | 4.270.552 | 1,18 | 37.500,00 | 1.875.000.000 | 160.145.700.000 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 100.000 | 4.220.552 | 2,43 | 50.000,00 | 5.000.000.000 | 211.027.600.000 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 100.000 | 4.220.552 | 2,43 | 50.000,00 | 5.000.000.000 | 211.027.600.000 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Convertible Notes |
C - Conversion | -2.271.694 | 4.120.552 | -35,54 | 1.135.847,23 | -2.580.297.337.308 | 4.680.317.575.271 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Convertible Notes |
C - Conversion | -2.271.694 | 4.120.552 | -35,54 | 1.135.847,23 | -2.580.297.337.308 | 4.680.317.575.271 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
P - Purchase | 606.833 | 6.420.141 | 10,44 | 0,50 | 303.416 | 3.210.070 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
P - Purchase | 606.833 | 6.420.141 | 10,44 | 0,50 | 303.416 | 3.210.070 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
P - Purchase | 638.750 | 5.813.308 | 12,34 | 0,50 | 319.375 | 2.906.654 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
P - Purchase | 638.750 | 5.813.308 | 12,34 | 0,50 | 319.375 | 2.906.654 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
P - Purchase | 1.026.111 | 5.174.558 | 24,73 | 0,50 | 513.056 | 2.587.279 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
P - Purchase | 1.026.111 | 5.174.558 | 24,73 | 0,50 | 513.056 | 2.587.279 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
P - Purchase | 100.000 | 4.148.447 | 2,47 | 0,50 | 50.000 | 2.074.224 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
P - Purchase | 100.000 | 4.148.447 | 2,47 | 0,50 | 50.000 | 2.074.224 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 250.000 | 6.350.552 | 4,10 | 125.000,00 | 31.250.000.000 | 793.819.000.000 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 250.000 | 6.350.552 | 4,10 | 125.000,00 | 31.250.000.000 | 793.819.000.000 | |
2014-02-13 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Stock Option |
A - Award | 57.958 | 7.867.928 | 0,74 | 31.877,00 | 1.847.527.166 | 250.805.940.856 | |
2013-11-06 |
|
4 | NVGN |
NOVOGEN LTD
Sponsored ADRs, each convertible into 25 ordinary shares |
S - Sale | -23.922 | 385.749 | -5,84 | 6,01 | -143.690 | 2.317.040 | |
2013-11-06 |
|
4 | NVGN |
NOVOGEN LTD
Sponsored ADRs, each convertible into 25 ordinary shares |
S - Sale | -25.400 | 409.671 | -5,84 | 6,02 | -153.032 | 2.468.227 | |
2013-10-29 |
|
4 | NVGN |
NOVOGEN LTD
Sponsored ADRs, each convertible into 25 ordinary shares |
S - Sale | -1.100 | 435.071 | -0,25 | 6,04 | -6.641 | 2.626.524 | |
2013-10-29 |
|
4 | NVGN |
NOVOGEN LTD
Sponsored ADRs, each convertible into 25 ordinary shares |
S - Sale | -37.409 | 436.171 | -7,90 | 6,18 | -231.236 | 2.696.104 | |
2013-10-29 |
|
4 | NVGN |
NOVOGEN LTD
Sponsored ADRs, each convertible into 25 ordinary shares |
S - Sale | -62.591 | 473.580 | -11,67 | 6,17 | -386.337 | 2.923.125 | |
2013-10-17 |
|
4 | NVGN |
NOVOGEN LTD
Sponsored ADRs, each convertible into 25 ordinary shares |
S - Sale | -90.025 | 536.171 | -14,38 | 6,21 | -559.208 | 3.330.533 | |
2013-10-01 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 225.000 | 6.100.552 | 3,83 | ||||
2013-10-01 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 225.000 | 6.100.552 | 3,83 | ||||
2013-10-01 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 6.100.552 | 300.000,00 | 1.830.165.600.000 | ||||
2013-10-01 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 6.100.552 | 300.000,00 | 1.830.165.600.000 | ||||
2013-09-16 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 236.250 | 5.275.552 | 4,69 | ||||
2013-09-16 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 236.250 | 5.275.552 | 4,69 | ||||
2013-09-16 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 5.275.552 | 315.000,00 | 1.661.798.880.000 | ||||
2013-09-16 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 5.275.552 | 315.000,00 | 1.661.798.880.000 | ||||
2013-09-16 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 375.000 | 4.409.302 | 9,30 | ||||
2013-09-16 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 375.000 | 4.409.302 | 9,30 | ||||
2013-09-16 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 4.409.302 | 500.000,00 | 2.204.651.000.000 | ||||
2013-09-16 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 4.409.302 | 500.000,00 | 2.204.651.000.000 | ||||
2013-09-16 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 196.802 | 3.034.302 | 6,94 | ||||
2013-09-16 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 196.802 | 3.034.302 | 6,94 | ||||
2013-09-16 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
P - Purchase | 262.403 | 4.048.447 | 6,93 | 0,50 | 131.202 | 2.024.224 | |
2013-09-16 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
P - Purchase | 262.403 | 4.048.447 | 6,93 | 0,50 | 131.202 | 2.024.224 | |
2013-08-30 |
|
4 | GDP |
GOODRICH PETROLEUM CORP
Common Stock |
S - Sale | -297.536 | 1.900.790 | -13,53 | 21,48 | -6.391.877 | 40.834.101 | |
2013-08-30 |
|
4 | GDP |
GOODRICH PETROLEUM CORP
Common Stock |
S - Sale | -253.816 | 2.198.326 | -10,35 | 21,35 | -5.419.352 | 46.937.558 | |
2013-08-27 |
|
4 | GDP |
GOODRICH PETROLEUM CORP
Common Stock |
S - Sale | -90.731 | 2.452.142 | -3,57 | 21,58 | -1.958.193 | 52.923.110 | |
2013-08-27 |
|
4 | GDP |
GOODRICH PETROLEUM CORP
Common Stock |
S - Sale | -57.917 | 2.542.873 | -2,23 | 21,85 | -1.265.457 | 55.560.504 | |
2013-08-27 |
|
4 | GDP |
GOODRICH PETROLEUM CORP
Common Stock |
S - Sale | -300.000 | 2.600.790 | -10,34 | 21,93 | -6.578.640 | 57.032.204 | |
2013-08-20 |
|
4 | GDP |
GOODRICH PETROLEUM CORP
Depositary Shares |
P - Purchase | 70.000 | 70.000 | 25,00 | 1.750.000 | 1.750.000 | ||
2013-06-14 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 210.000 | 3.275.000 | 6,85 | ||||
2013-06-14 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 210.000 | 3.275.000 | 6,85 | ||||
2013-06-14 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
P - Purchase | 280.000 | 3.786.044 | 7,99 | 0,50 | 140.000 | 1.893.022 | |
2013-06-14 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
P - Purchase | 280.000 | 3.786.044 | 7,99 | 0,50 | 140.000 | 1.893.022 | |
2013-05-23 |
|
4 | GDP |
GOODRICH PETROLEUM CORP
Common Stock |
A - Award | 6.000 | 82.600 | 7,83 | 13,61 | 81.660 | 1.124.186 | |
2013-04-12 |
|
4 | GDP |
GOODRICH PETROLEUM CORP
Depositary Shares |
P - Purchase | 60.000 | 60.000 | 25,00 | 1.500.000 | 1.500.000 | ||
2013-03-25 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 1.027.500 | 3.065.000 | 50,43 | ||||
2013-03-25 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 1.027.500 | 3.065.000 | 50,43 | ||||
2013-03-25 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
P - Purchase | 1.370.000 | 3.506.044 | 64,14 | 0,50 | 685.000 | 1.753.022 | |
2013-03-25 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
P - Purchase | 1.370.000 | 3.506.044 | 64,14 | 0,50 | 685.000 | 1.753.022 | |
2013-02-27 |
|
4 | NVGN |
NOVOGEN LTD
Sponsored ADRs, each convertible into 25 ordinary shares |
S - Sale | -500 | 626.196 | -0,08 | 8,00 | -4.000 | 5.009.568 | |
2013-02-27 |
|
4 | NVGN |
NOVOGEN LTD
Sponsored ADRs, each convertible into 25 ordinary shares |
S - Sale | -500 | 626.696 | -0,08 | 9,03 | -4.515 | 5.659.065 | |
2013-02-27 |
|
4 | NVGN |
NOVOGEN LTD
Sponsored ADRs, each convertible into 25 ordinary shares |
S - Sale | -500 | 627.196 | -0,08 | 9,21 | -4.605 | 5.776.475 | |
2013-02-27 |
|
4 | NVGN |
NOVOGEN LTD
Sponsored ADRs, each convertible into 25 ordinary shares |
S - Sale | -500 | 627.696 | -0,08 | 9,15 | -4.575 | 5.743.418 | |
2013-02-27 |
|
4 | NVGN |
NOVOGEN LTD
Sponsored ADRs, each convertible into 25 ordinary shares |
S - Sale | -500 | 628.196 | -0,08 | 9,10 | -4.550 | 5.716.584 | |
2013-02-27 |
|
4 | NVGN |
NOVOGEN LTD
Sponsored ADRs, each convertible into 25 ordinary shares |
S - Sale | -500 | 628.696 | -0,08 | 9,05 | -4.525 | 5.689.699 | |
2013-02-27 |
|
4 | NVGN |
NOVOGEN LTD
Sponsored ADRs, each convertible into 25 ordinary shares |
S - Sale | -500 | 629.196 | -0,08 | 8,90 | -4.450 | 5.599.844 | |
2013-01-07 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 187.500 | 4.173.544 | 4,70 | ||||
2013-01-07 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Warrant |
P - Purchase | 187.500 | 4.173.544 | 4,70 | ||||
2013-01-07 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 4.173.544 | 125.000,00 | 521.693.000.000 | ||||
2013-01-07 |
|
4 | NONE |
Protea Biosciences Group, Inc.
Convertible Note |
P - Purchase | 4.173.544 | 125.000,00 | 521.693.000.000 | ||||
2012-12-20 | 3 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
2.136.044 | ||||||||
2012-12-20 | 3 | NONE |
Protea Biosciences Group, Inc.
Common Stock |
2.136.044 | ||||||||
2012-12-19 |
|
4 | GDP |
GOODRICH PETROLEUM CORP
Common Stock |
S - Sale | -50.000 | 2.900.790 | -1,69 | 9,21 | -460.700 | 26.727.879 | |
2012-12-19 |
|
4 | GDP |
GOODRICH PETROLEUM CORP
Common Stock |
S - Sale | -250.000 | 2.950.790 | -7,81 | 8,08 | -2.019.700 | 23.838.842 | |
2012-12-18 |
|
4 | CHTP |
Chelsea Therapeutics International, Ltd.
Common Stock |
S - Sale | -439.308 | 6.432.673 | -6,39 | 0,92 | -402.055 | 5.887.182 | |
2012-12-18 |
|
4 | CHTP |
Chelsea Therapeutics International, Ltd.
Common Stock |
S - Sale | -249.249 | 6.871.981 | -3,50 | 0,95 | -236.811 | 6.529.069 | |
2012-12-14 |
|
4 | CHTP |
Chelsea Therapeutics International, Ltd.
Common Stock |
S - Sale | -399.414 | 7.121.230 | -5,31 | 1,05 | -419.385 | 7.477.292 | |
2012-12-11 |
|
4 | MEIP |
MEI Pharma, Inc.
Warrants to purchase shares of common stock |
J - Other | 1.000.000 | 1.000.000 | |||||
2012-12-11 |
|
4 | CHTP |
Chelsea Therapeutics International, Ltd.
Common Stock |
S - Sale | -139.653 | 7.520.644 | -1,82 | 1,05 | -146.636 | 7.896.676 | |
2012-12-11 |
|
4 | CHTP |
Chelsea Therapeutics International, Ltd.
Common Stock |
S - Sale | -230.407 | 7.660.297 | -2,92 | 1,00 | -230.522 | 7.664.127 | |
2012-12-07 |
|
4 | CHTP |
Chelsea Therapeutics International, Ltd.
Common Stock |
S - Sale | -235.009 | 7.890.704 | -2,89 | 1,07 | -251.460 | 8.443.053 | |
2012-12-07 |
|
4 | CHTP |
Chelsea Therapeutics International, Ltd.
Common Stock |
S - Sale | -154.836 | 8.125.713 | -1,87 | 1,18 | -182.706 | 9.588.341 | |
2012-12-05 |
|
4 | MEIP |
MEI Pharma, Inc.
Common stock, par value $0.00000002 per share |
J - Other | 3.478.245 | 3.832.081 | 983,01 | ||||
2012-12-05 | 3 | MEIP |
MEI Pharma, Inc.
Common stock, par value $0.00000002 per share |
3.832.081 | ||||||||
2012-05-21 |
|
4 | GDP |
GOODRICH PETROLEUM CORP
Common Stock |
A - Award | 6.000 | 76.600 | 8,50 | 13,38 | 80.280 | 1.024.908 | |
2012-01-30 |
|
4 | CHTP |
Chelsea Therapeutics International, Ltd.
Common Stock |
P - Purchase | 4.000 | 8.305.049 | 0,05 | 4,50 | 18.008 | 37.388.500 | |
2012-01-30 |
|
4 | CHTP |
Chelsea Therapeutics International, Ltd.
Common Stock |
P - Purchase | 13.900 | 8.301.049 | 0,17 | 4,46 | 61.994 | 37.022.679 | |
2012-01-30 |
|
4 | CHTP |
Chelsea Therapeutics International, Ltd.
Common Stock |
P - Purchase | 4.000 | 8.287.149 | 0,05 | 4,43 | 17.720 | 36.712.070 | |
2012-01-24 |
|
4 | CHTP |
Chelsea Therapeutics International, Ltd.
Common Stock |
P - Purchase | 40.000 | 8.283.149 | 0,49 | 4,80 | 192.000 | 39.759.115 |